Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 1.97B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -105.04M |
| Shares Out | 57.84M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,501 |
| Open | 35.00 |
| Previous Close | 35.10 |
| Day's Range | 33.62 - 35.85 |
| 52-Week Range | 4.30 - 40.37 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 44.63 (+31.34%) |
| Earnings Date | May 12, 2026 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price target is $44.63, which is an increase of 31.34% from the latest price.
News
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates
Capricor posted a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period.
Capricor Therapeutics Earnings Call Transcript: Q4 2025
BLA for Deramiocel accepted by FDA with PDUFA date set for August 2026, following strong HOPE-3 trial results showing efficacy in DMD. Cash position is robust at $318M, with manufacturing expansion and commercial launch preparations underway.
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday morning after the biotech company said the U.S. Food and Drug Administration resumed its review of the Biologics License Appli...
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Research (CBER), is set to leave his position...
Capricor Therapeutics Transcript: Study Result
The phase III HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy met its primary and key secondary endpoints, showing significant slowing of upper limb and cardiac deterioration with a strong safety profile. Regulatory submission is planned, and the therapy is positioned for use alongside other treatments.
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the comm...
Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say
Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.
Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Positive phase III data for deramiocel in DMD showed significant improvements in both cardiac and skeletal muscle function, supporting a broad label and full FDA approval. Commercial manufacturing is ready, partnerships are in place, and expansion into new indications and exosome-based therapies is planned.
Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial
Capricor Therapeutics Inc. (NASDAQ: CAPR) stock is rallying on Wednesday.
Capricor Therapeutics Transcript: Status Update
HOPE-3 phase III data for deramiocel in Duchenne muscular dystrophy showed significant improvements in both skeletal and cardiac function, meeting all primary and secondary endpoints with strong safety and tolerability. The results address FDA concerns, support broad patient use, and position the therapy for regulatory approval and commercial launch.
Capricor's muscle disorder cell therapy succeeds in late-stage study
Capricor Therapeutics said on Wednesday its cell therapy for a heart condition related to a rare muscular disorder met the main goal of a late-stage study, months after U.S. regulators rejected its in...
Martin Shkreli Takes Aim At Capricor — Stock Sinks
Shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) plummeted Monday due to a short call from controversial former pharmaceutical executive Martin Shkreli.
Capricor Therapeutics Earnings Call Transcript: Q3 2025
Top-line HOPE-3 data for Deramiocel in Duchenne muscular dystrophy is imminent, with FDA review and potential approval targeted for 2026. Cash reserves of $98.6 million support operations into late 2026, and a strong safety profile and commercial readiness position the company for launch if approved.
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
–Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development–
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misco...
Capricor Therapeutics Transcript: Study Update
FDA will review HOPE-3 trial data for DMD, allowing both skeletal and cardiac endpoints for potential dual labeling. Top-line results are expected mid-November, with strong safety and efficacy powering, and financial resources support launch readiness.
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today annou...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Capricor To Contact Him Directly To Discuss Their Options If you su...
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issue...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acquire...